瓦美司他治疗复发或难治性成人T细胞白血病/淋巴瘤的开放标签单臂2期试验
这项多中心2期试验纳入25例复发或难治性侵袭性成人T细胞白血病/淋巴瘤(ATL)患者,口服瓦美司他200 mg/天直至疾病进展或不可耐受毒性。中心审查的总体缓解率为48.0%(90%CI 30.5-65.9),中位缓解持续时间未达到;常见治疗中出现的不良事件可管理,研究结论认为疗效值得进一步研究。
要点
- 中心审查总体缓解率48.0%(90%CI 30.5-65.9),含5例完全缓解和7例部分缓解。
- 既往接受莫格利珠单抗治疗者总体缓解率45.8%(4例完全缓解、7例部分缓解)。
- 治疗中出现的不良事件可管理,≥20%者包括血小板减少、贫血、脱发、味觉障碍等。
核心结论
- 瓦美司他在重度经治的复发或难治性ATL患者中显示出有前景的疗效和耐受性,值得进一步研究。
研究设计与样本
- 多中心、开放标签、单臂2期试验,纳入复发或难治性侵袭性ATL(急性型、淋巴瘤型、不良慢性型)患者。
- 患者接受瓦美司他200 mg/天口服,直至疾病进展或不可接受的毒性。
- 主要终点为由独立疗效评估委员会(IEAC)中心评估的总体缓解率(ORR);次要终点包括各疾病部位的最佳缓解、缓解持续时间(DOR)、药代动力学和安全性。
- 共纳入25例患者,中位年龄69.0岁,既往治疗中位线数为3线;24例既往接受过莫格利珠单抗治疗。
- 试验注册号:NCT04102150。
主要发现
- 中心审查的总体缓解率为48.0%(90%CI 30.5-65.9),包括5例完全缓解和7例部分缓解。
- 既往接受莫格利珠单抗治疗的患者总体缓解率为45.8%(4例完全缓解、7例部分缓解)。
- IEAC评估的中位缓解持续时间未达到(NR)(95%CI 1.87至NR;月)。
- 治疗中出现的不良事件(TEAE)可管理;发生率≥20%的TEAE包括血小板减少、贫血、脱发、味觉障碍、中性粒细胞减少、淋巴细胞减少、白细胞减少、食欲下降和发热。
- ≥3级TEAE包括血小板减少、贫血、淋巴细胞减少、白细胞减少和中性粒细胞减少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论提出瓦美司他值得进一步研究(warranting further investigation),未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients with relapsed, recurrent, or refractory disease. We evaluated the efficacy and safety of valemetostat, a potent enhancer of zeste homolog 2 (EZH2) and EZH1 inhibitor, in treating relapsed or refractory (R/R) ATL. This multicenter phase 2 trial enrolled patients with R/R aggressive ATL (acute, lymphoma, unfavorable chronic type). Patients received valemetostat 200 mg/day orally until progressive disease or unacceptable toxicity. The primary end point was overall response rate (ORR) centrally assessed by an independent efficacy assessment committee (IEAC). Secondary end points included best response in disease compartments, duration of response (DOR), pharmacokinetics, and safety. Twenty-five patients (median age, 69.0 years) with a median of 3 prior lines of therapy were enrolled; 24 had prior mogamulizumab treatment. The primary end point was met with a centrally reviewed ORR of 48.0% (90% confidence interval [CI], 30.5-65.9), including 5 complete and 7 partial remissions. Patients pretreated with mogamulizumab had an ORR of 45.8% (4 complete and 7 partial remissions). IEAC-assessed median DOR was not reached (NR) (95% CI, 1.87 to NR; months). Treatment-emergent adverse events (TEAEs) were manageable. TEAEs that occurred in ≥20% of patients included thrombocytopenia, anemia, alopecia, dysgeusia, neutropenia, lymphopenia, leukopenia, decreased appetite, and pyrexia. Grade ≥3 TEAEs included thrombocytopenia, anemia, lymphopenia, leukopenia, and neutropenia. Valemetostat demonstrated promising efficacy and tolerability in heavily pretreated patients, warranting further investigation in treating R/R ATL. This trial was registered at www.clinicaltrials.gov as #NCT04102150.
引用
- Izutsu K, Makita S, Nosaka K, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood. 2023. PMID: 36150143. doi:10.1182/blood.2022016862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。